Financhill
Back

Sangamo Therapeutics Quote, Financials, Valuation and Earnings

7 Powerhouse Stocks to Buy and Hold Forever

Get it now.
Sell
29

SGMO
Sangamo Therapeutics

Last Price:
0.53
Seasonality Move:
-2.28%

7 Day Trial

ALL ACCESS PASS

$ 7

9,530x the last time this happened

Here's what our expert says you should buy before April 14.

Sangamo Therapeutics Price Quote

$0.53
+0.01 (+1.53%)
(Updated: May 3, 2024 at 12:55 PM ET)

Sangamo Therapeutics Key Stats

Sell
29
Sangamo Therapeutics (SGMO) is a Sell

Day range:
$0.52 - $0.57
52-week range:
$0.29 - $1.67
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.52
P/B ratio:
1.13%

Volume:
746.6K
Avg. volume:
1.8M
1-year change:
-61.9%
Market cap:
$93.4M
Revenue:
$176.2M
EPS:
$-1.47

How Much Does Sangamo Therapeutics Make?

Is Sangamo Therapeutics Growing As A Company?

  • What Is Sangamo Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.93%
  • What Is Sangamo Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Sangamo Therapeutics Stock Price Performance

What Is Sangamo Therapeutics 52-Week High & Low?

Sangamo Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Sangamo Therapeutics?

Is Sangamo Therapeutics Cash Flow Positive?

  • What Is SGMO Cash Flow From Operations?
    Cash flow from operations (TTM) is -$224.8M
  • What Is Sangamo Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $14.6M
  • What Is Sangamo Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $153.5M

Sangamo Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    SGMO return on invested capital is -119.14%
  • What Is Sangamo Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -75.25%
  • What Is SGMO Return On Equity?
    ROE is a measure of profitability and is -119.14%

Sangamo Therapeutics Earnings Date & Stock Price

Sangamo Therapeutics Competitors

  • Who Are Sangamo Therapeutics's Competitors?
    Below is a list of companies who compete with Sangamo Therapeutics or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Armata Pharmaceuticals Inc (ARMP)
    • Perspective Therapeutics Inc (CATX)
    • Electromed Inc (ELMD)
    • Protalix BioTherapeutics Inc (PLX)

Sangamo Therapeutics Dividend Yield

Data Unavailable

Sangamo Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -8.97%
Revenue: -92.5% -74.81%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 4
Sell Recommendations: 0
Price Target: 3.50
Upside from Last Price: 570.5%

Major Shareholders

  • How many SGMO shares are owned by institutional investors?
    112M SGMO shares are owned by institutional investors
  • How many SGMO shares are owned by insiders?
    8.6M SGMO shares are owned by insiders